Key result
Diverse LMNA mutations in iPSC-derived cardiomyocytes and cardiac fibroblasts resulted in variable perturbations in LMNA expression, ERK pathway activation, nuclear morphology, and electrophysiology.
Why the study?
Mutations in LMNA cause familial arrhythmogenic cardiomyopathy with considerable phenotypic variability, but whether this variability stems from specific LMNA mutation sites and types remains to be addressed.
Population
Seven patient-specific iPSC lines with various LMNA mutations differentiated into iCMs and iCFs
Comparison
Different LMNA mutation sites and types across iCMs and iCFs, including coculture
Design
Preclinical in vitro iPSC modeling study
Authors
Loading...
Supports genotype-specific therapy exploration in LMNA cardiomyopathy; hypothesis-generating and should not yet change practice.
Patient-specific iPSC models reveal that different LMNA mutations cause distinct phenotypic and mechanistic heterogeneities in cardiomyocytes and cardiac fibroblasts, highlighting the need for genotype-specific therapeutic approaches.
Yang et al. (2021) studied LMNA-related cardiomyopathy (n=7). LMNA mutations vs. Healthy controls was evaluated on Cellular phenotypic alterations (LMNA expression, ERK pathway activation, apoptosis, nuclear morphology, and electrophysiology). Diverse LMNA mutations in iPSC-derived cardiomyocytes and cardiac fibroblasts resulted in variable perturbations in LMNA expression, ERK pathway activation, nuclear morphology, and electrophysiology.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: